Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-atopic-dermatitis-global-drug-forecast-and-market-analysis-to-2022-market-report.html .
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.
